CN105748465A - 用于治疗癌症的多激酶抑制剂 - Google Patents

用于治疗癌症的多激酶抑制剂 Download PDF

Info

Publication number
CN105748465A
CN105748465A CN201610165747.1A CN201610165747A CN105748465A CN 105748465 A CN105748465 A CN 105748465A CN 201610165747 A CN201610165747 A CN 201610165747A CN 105748465 A CN105748465 A CN 105748465A
Authority
CN
China
Prior art keywords
compound
formula
cancer
certain embodiments
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201610165747.1A
Other languages
English (en)
Chinese (zh)
Inventor
谢尔盖·阿古尔尼克
布鲁斯·德科斯塔
杜红
江逸民
李祥逸
野本见
野本见一
约翰(元)·王
张慧明
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai R&D Management Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co Ltd filed Critical Eisai R&D Management Co Ltd
Publication of CN105748465A publication Critical patent/CN105748465A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CN201610165747.1A 2007-07-25 2008-07-25 用于治疗癌症的多激酶抑制剂 Pending CN105748465A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US95190607P 2007-07-25 2007-07-25
US95190107P 2007-07-25 2007-07-25
US60/951,901 2007-07-25
US60/951,906 2007-07-25
US2919608P 2008-02-15 2008-02-15
US61/029,196 2008-02-15

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN200880023760.7A Division CN101778627B (zh) 2007-07-25 2008-07-25 用于治疗癌症的多激酶抑制剂

Publications (1)

Publication Number Publication Date
CN105748465A true CN105748465A (zh) 2016-07-13

Family

ID=40121184

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201610165747.1A Pending CN105748465A (zh) 2007-07-25 2008-07-25 用于治疗癌症的多激酶抑制剂
CN200880023760.7A Active CN101778627B (zh) 2007-07-25 2008-07-25 用于治疗癌症的多激酶抑制剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN200880023760.7A Active CN101778627B (zh) 2007-07-25 2008-07-25 用于治疗癌症的多激酶抑制剂

Country Status (10)

Country Link
US (4) US8609640B2 (https=)
EP (1) EP2182941B1 (https=)
JP (2) JP5484327B2 (https=)
KR (3) KR101721161B1 (https=)
CN (2) CN105748465A (https=)
AU (1) AU2008279027B8 (https=)
CA (1) CA2698271C (https=)
ES (1) ES2670423T3 (https=)
IL (2) IL202307A (https=)
WO (1) WO2009015368A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003224672B2 (en) * 2002-03-08 2010-02-04 Eisai R&D Management Co., Ltd. Macrocyclic compounds useful as pharmaceuticals
US8609640B2 (en) 2007-07-25 2013-12-17 Eisai, Inc. Multikinase inhibitors for use in the treatment of cancer
AU2008318690B2 (en) * 2007-10-29 2015-08-13 Eisai R & D Management Co., Ltd. Methods for prognosing the ability of a zearalenone analog compound to treat cancer
BRPI0820958B1 (pt) * 2007-12-07 2022-04-05 Eisai R&D Management Co., Ltd Compostos macrolídeos
US8426418B2 (en) 2010-08-27 2013-04-23 CollabRx Inc. Method to treat melanoma in BRAF inhibitor-resistant subjects
KR102265952B1 (ko) * 2013-06-26 2021-06-16 에자이 알앤드디 매니지먼트 가부시키가이샤 암 치료 병용요법으로서 에리불린 및 렌바티닙의 용도
PT3039424T (pt) 2013-08-28 2020-09-03 Crown Bioscience Inc Taicang Assinaturas de expressão genética que permitem prever a resposta de um sujeito a um inibidor multiquinase e métodos de utilização do mesmo
WO2015181628A1 (en) * 2014-05-27 2015-12-03 Eisai R&D Management Co., Ltd. Treatment of acute myeloid leukemia with an hck inhibitor
WO2022053130A1 (en) * 2020-09-09 2022-03-17 Sid Alex Group, S.R.O. Antago-mir-155 for treatment of v-src, c-src-tyrosine kinase-induced cancers

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1653059A (zh) * 2002-03-08 2005-08-10 卫材株式会社 用作医药品的大环化合物
US20060079494A1 (en) * 2004-09-27 2006-04-13 Santi Daniel V Specific kinase inhibitors

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9225396D0 (en) 1992-12-04 1993-01-27 Sandoz Ltd Improvements in or relating to organic compounds
JPH0840893A (ja) 1993-08-31 1996-02-13 Takeda Chem Ind Ltd インターロイキン−１産生抑制剤
DE4420930C2 (de) 1994-06-16 1997-05-22 Daimler Benz Ag Vorrichtung und Verfahren zum Steuern einer selbsttätigen Schaltvorrichtung eines Gangwechselgetriebes eines Kraftfahrzeuges
US5795910A (en) 1994-10-28 1998-08-18 Cor Therapeutics, Inc. Method and compositions for inhibiting protein kinases
US5727726A (en) * 1996-06-14 1998-03-17 Newco Pneumatic Corp. Cassette assembly for a stapling mechanism
US6265603B1 (en) 1997-02-27 2001-07-24 Eisai Co., Ltd. Inhibitors of isoprenyl transferase
GB2323845A (en) 1997-03-31 1998-10-07 Merck & Co Inc MEK inhibiting lactones
US6635671B1 (en) 1998-12-24 2003-10-21 Novation Pharmaceuticals Inc. Compounds which affect mRNA stability and uses therefor
GB9828709D0 (en) 1998-12-24 1999-02-17 Novartis Ag Assay
KR20050005569A (ko) * 1999-03-29 2005-01-13 샤이어 바이오켐 인코포레이티드 백혈병 치료방법
WO2001036003A2 (en) 1999-11-15 2001-05-25 Drug Innovation & Design, Inc. Selective cellular targeting: multifunctional delivery vehicles
US7833698B2 (en) 2000-01-12 2010-11-16 Ventana Medical Systems, Inc. Method for determining the response to cancer therapy
JP2001294527A (ja) 2000-04-14 2001-10-23 Ajinomoto Co Inc Ｔｈ２反応に特異的な免疫寛容誘導剤
CA2406443C (en) 2000-04-14 2009-06-23 Ventana Medical Systems, Inc. Method for quantification of akt protein expression
JP2004292315A (ja) 2000-12-14 2004-10-21 Chugai Pharmaceut Co Ltd Ｔａｋ１阻害剤
JP2004292314A (ja) 2000-12-14 2004-10-21 Chugai Pharmaceut Co Ltd ケラチノサイト増殖抑制剤
US7071164B2 (en) 2001-08-16 2006-07-04 Kimberly-Clark Worldwide, Inc. Anti-cancer and wound healing compounds
EP2277991A1 (en) 2001-08-21 2011-01-26 Ventana Medical Systems, Inc. Method and quantification assay for determining c-kit/SCF/pAKT status
NZ532780A (en) 2001-12-21 2006-10-27 Wellcome Trust Isolated naturally occurring mutant human B-Raf polypeptides and nucleic acids encoding them
US20040096855A1 (en) 2001-12-24 2004-05-20 Michael Stratton Genes
US7915306B2 (en) 2002-03-08 2011-03-29 Eisai Co., Ltd. Macrocyclic compounds useful as pharmaceuticals
EA010485B1 (ru) 2003-07-23 2008-10-30 Байер Фамэсьютиклс Копэрейшн Производное n,n'-дифенилмочевины, фармацевтическая композиция (варианты) и способ лечения и предупреждения заболеваний и состояний с его использованием (варианты)
AU2003286447A1 (en) 2003-10-16 2004-06-06 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Treatments for inhibiting development and progression of nevi and melanoma having braf mutations
US20050214325A1 (en) 2004-03-26 2005-09-29 Vvii Newco 2003, Inc. Compositions and methods to increase the effect of a neurotoxin treatment
BRPI0508970A (pt) 2004-03-19 2007-08-21 Penn State Res Found método combinatórios e composições para o tratamento de melanoma
CA2561516A1 (en) 2004-03-30 2005-10-13 Pfizer Products Inc. Combinations of signal transduction inhibitors
MXPA06014021A (es) 2004-06-04 2007-02-08 Pfizer Prod Inc Procedimiento para tratar crecimiento celular anormal.
US20060216288A1 (en) 2005-03-22 2006-09-28 Amgen Inc Combinations for the treatment of cancer
US7812143B2 (en) 2006-03-31 2010-10-12 Memorial Sloan-Kettering Cancer Center Biomarkers for cancer treatment
US8609640B2 (en) 2007-07-25 2013-12-17 Eisai, Inc. Multikinase inhibitors for use in the treatment of cancer
AU2008318690B2 (en) 2007-10-29 2015-08-13 Eisai R & D Management Co., Ltd. Methods for prognosing the ability of a zearalenone analog compound to treat cancer
BRPI0820958B1 (pt) 2007-12-07 2022-04-05 Eisai R&D Management Co., Ltd Compostos macrolídeos
US8578879B2 (en) * 2009-07-29 2013-11-12 Applied Materials, Inc. Apparatus for VHF impedance match tuning

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1653059A (zh) * 2002-03-08 2005-08-10 卫材株式会社 用作医药品的大环化合物
US20060079494A1 (en) * 2004-09-27 2006-04-13 Santi Daniel V Specific kinase inhibitors

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANNE-MARIE O’FARRELL: "An Innovative Phase I Clinical Study Demonstrates Inhibition of FLT3 Phosphorylation by SU11248 in Acute Myeloid Leukemia Patients", 《CLINICAL CANCER RESEARCH》 *
PANAGIOTIS D. KOTTARIDIS: "The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingd", 《BLOOD》 *
徐兵 等: "慢性粒细胞白血病FLT3基因及FLT3/ITD基因突变的检测及意义", 《癌症》 *

Also Published As

Publication number Publication date
KR20160123390A (ko) 2016-10-25
US11160783B2 (en) 2021-11-02
JP5484327B2 (ja) 2014-05-07
WO2009015368A3 (en) 2009-03-26
KR20100044868A (ko) 2010-04-30
CA2698271C (en) 2016-07-05
KR101721161B1 (ko) 2017-03-29
KR101573026B1 (ko) 2015-11-30
CN101778627B (zh) 2016-04-13
IL202307A (en) 2016-08-31
AU2008279027A8 (en) 2014-03-06
ES2670423T3 (es) 2018-05-30
EP2182941B1 (en) 2018-02-28
AU2008279027B2 (en) 2014-02-06
US8937056B2 (en) 2015-01-20
US20180353468A1 (en) 2018-12-13
US20130303489A1 (en) 2013-11-14
AU2008279027A1 (en) 2009-01-29
CA2698271A1 (en) 2009-01-29
KR101667960B1 (ko) 2016-10-20
US20150182496A1 (en) 2015-07-02
CN101778627A (zh) 2010-07-14
WO2009015368A2 (en) 2009-01-29
IL247230A (en) 2017-04-30
US20090082313A1 (en) 2009-03-26
AU2008279027B8 (en) 2014-03-06
EP2182941A2 (en) 2010-05-12
IL202307A0 (en) 2010-06-30
JP2013189458A (ja) 2013-09-26
KR20150138417A (ko) 2015-12-09
US8609640B2 (en) 2013-12-17
JP2010534682A (ja) 2010-11-11

Similar Documents

Publication Publication Date Title
CN105748465A (zh) 用于治疗癌症的多激酶抑制剂
US10954202B2 (en) Protein tyrosine phosphatase inhibitors and methods of use thereof
TW202100515A (zh) 蛋白酪胺酸磷酸酶抑制劑及其使用方法
US10308658B2 (en) Salt of EGFR inhibitor, crystalline form and uses thereof
CA2940576A1 (en) Therapeutic combinations with estrogen receptor modulators
JP2019528318A (ja) 血液脳関門通過能を有する置換キナゾリン化合物
US20230019236A1 (en) Protein tyrosine phosphatase inhibitors and methods of use thereof
CN110357858A (zh) 具有穿过血脑屏障能力的5取代二氟哌啶化合物
CN108586443A (zh) 一种防治支气管肺癌的药物及其制备方法
CN109729716A (zh) Pi3k-抑制剂的组合产品
JP2014515026A (ja) アカデシン誘導体、それを含有する製剤および組成物、その治療目的での使用、ならびにその合成法
CN109415382A (zh) 皮质抑素类似物
WO2019196622A1 (zh) 具有穿过血脑屏障能力的5取代二氟哌啶化合物
JP7354245B2 (ja) ピロロピリミジン骨格を有する新規なカーボネート化合物又はその薬学的に許容可能な塩
RU2799446C2 (ru) Ингибиторы протеин-тирозинфосфатазы и способы их применения
TW200924749A (en) Zearalenone macrolide derivatives and uses of the same
CN107163061A (zh) 含吡唑啉结构的噻吩并嘧啶类化合物的制备及应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20160713

RJ01 Rejection of invention patent application after publication